Denmark's Novo Nordisk denies Wegovy shortage, despite Danish Medicines Agency warning; all doses now available, with occasional backorders due to high demand.

Denmark's Novo Nordisk denies possible Wegovy shortage despite Danish Medicines Agency's warning of limited supply in May-June, and mid-June to mid-July due to heightened demand. The company confirms all Wegovy doses are now available in Denmark, with occasional backorders due to high demand. Wegovy, a weekly injection, is a GLP-1 agonist initially developed for type 2 diabetes.